Halozyme Therapeutics, Inc. (LON:0J2O)

Market Cap	6.23B +11.5%
Revenue (ttm)	1.14B +39.1%
Net Income	264.18M -28.1%
EPS	2.15 -24.4%
Shares Out	n/a
PE Ratio	23.58
Forward PE	8.03
Dividend	n/a
Ex-Dividend Date	n/a

Volume	994
Average Volume	713
Open	71.82
Previous Close	71.36
Day's Range	68.27 - 72.00
52-Week Range	47.68 - 84.23
Beta	0.88
RSI	63.31
Earnings Date	May 11, 2026

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) admini...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 423
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0J2O

Financial Performance

In 2025, Halozyme Therapeutics's revenue was $1.40 billion, an increase of 37.55% compared to the previous year's $1.02 billion. Earnings were $316.89 million, a decrease of -28.64%.

Financial numbers in USD